Long-term mortality and predictive score performance in Brazilian atherosclerotic renovascular disease patients.

IF 1.6 Q3 UROLOGY & NEPHROLOGY
Julia Gheller Salome, Lucas Peres Moraes, Rodrigo Hagemann, Vanessa Dos Santos Silva, Fabio Cardoso Carvalho, Roberto Jorge da Silva Franco, Diana Vassallo, Luis Cuadrado Martin, Philip A Kalra, Pasqual Barretti
{"title":"Long-term mortality and predictive score performance in Brazilian atherosclerotic renovascular disease patients.","authors":"Julia Gheller Salome, Lucas Peres Moraes, Rodrigo Hagemann, Vanessa Dos Santos Silva, Fabio Cardoso Carvalho, Roberto Jorge da Silva Franco, Diana Vassallo, Luis Cuadrado Martin, Philip A Kalra, Pasqual Barretti","doi":"10.1590/2175-8239-JBN-2024-0181en","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Atherosclerotic renovascular disease (ARVD) can cause renal artery stenosis, hypertension, and chronic kidney disease. As revascularization procedure for ARVD is controversial, a risk score was developed to predict mortality in affected patients, which requires validation in different populations. The original risk score did not include statin use; therefore, the aim of this study was to evaluate the accuracy of the risk score in ARVD patients according to statins intake.</p><p><strong>Methods: </strong>Longitudinal retrospective study involving 136 patients with angiographic diagnosis of RAS > 60% from January 1996 to October 2008. Cox regression analysis was performed to assess all-cause mortality associations. To evaluate the discriminatory power of the risk score, ROC curves were constructed for mortality at 1, 5, and 10 years for those with and without statin use.</p><p><strong>Results: </strong>103 patients were included, 69 of whom were taking statins. After 1, 5, and 10 years, survival rates predicted by the risk score for patients using statins were, respectively, 0.87 (95% CI [0.76;0.97]), 0. 45 (95% CI [0.37;0.55]), and 0.15 (95% CI [0.09;0.22]). Actual survival rates were 0.95, 0.88, and 0.72. For the 34 patients who did not use statins, predicted survival rates were 0.84 (95% CI [0.71;0.97]), 0.43 (IC 95% [0.32;0.55]), and 0.14 (95% CI [0.05;0.22]); actual survival rates were 0.83, 0.36, and 0.29.</p><p><strong>Conclusion: </strong>Patients receiving statins had greater survival rate after 5 and 10 years when compared to calculations by the risk score. The 34 patients who did not use statins had survival rates close to the predicted survival. Therefore, the risk score should be modified to include use of statins.</p>","PeriodicalId":14724,"journal":{"name":"Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia","volume":"47 4","pages":"e20240181"},"PeriodicalIF":1.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517691/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/2175-8239-JBN-2024-0181en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Atherosclerotic renovascular disease (ARVD) can cause renal artery stenosis, hypertension, and chronic kidney disease. As revascularization procedure for ARVD is controversial, a risk score was developed to predict mortality in affected patients, which requires validation in different populations. The original risk score did not include statin use; therefore, the aim of this study was to evaluate the accuracy of the risk score in ARVD patients according to statins intake.

Methods: Longitudinal retrospective study involving 136 patients with angiographic diagnosis of RAS > 60% from January 1996 to October 2008. Cox regression analysis was performed to assess all-cause mortality associations. To evaluate the discriminatory power of the risk score, ROC curves were constructed for mortality at 1, 5, and 10 years for those with and without statin use.

Results: 103 patients were included, 69 of whom were taking statins. After 1, 5, and 10 years, survival rates predicted by the risk score for patients using statins were, respectively, 0.87 (95% CI [0.76;0.97]), 0. 45 (95% CI [0.37;0.55]), and 0.15 (95% CI [0.09;0.22]). Actual survival rates were 0.95, 0.88, and 0.72. For the 34 patients who did not use statins, predicted survival rates were 0.84 (95% CI [0.71;0.97]), 0.43 (IC 95% [0.32;0.55]), and 0.14 (95% CI [0.05;0.22]); actual survival rates were 0.83, 0.36, and 0.29.

Conclusion: Patients receiving statins had greater survival rate after 5 and 10 years when compared to calculations by the risk score. The 34 patients who did not use statins had survival rates close to the predicted survival. Therefore, the risk score should be modified to include use of statins.

Abstract Image

Abstract Image

Abstract Image

巴西动脉粥样硬化性肾血管疾病患者的长期死亡率和预测评分表现
简介:动脉粥样硬化性肾血管疾病(ARVD)可引起肾动脉狭窄、高血压和慢性肾脏疾病。由于ARVD的血运重建术存在争议,因此开发了一种风险评分来预测受影响患者的死亡率,这需要在不同人群中进行验证。最初的风险评分不包括他汀类药物的使用;因此,本研究的目的是根据他汀类药物的摄入量来评估ARVD患者风险评分的准确性。方法:对1996年1月至2008年10月136例经血管造影诊断为RAS血栓的患者进行纵向回顾性研究。采用Cox回归分析评估全因死亡率的相关性。为了评估风险评分的区分能力,构建了使用和未使用他汀类药物的1、5和10年死亡率的ROC曲线。结果:纳入103例患者,其中69例正在服用他汀类药物。在1年、5年和10年后,使用他汀类药物患者的风险评分预测的生存率分别为0.87 (95% CI[0.76;0.97])、0。45 (95% CI[0.37, 0.55]),和0.15(95%可信区间[0.09,0.22])。实际生存率分别为0.95、0.88和0.72。对于34例未使用他汀类药物的患者,预测生存率分别为0.84 (95% CI[0.71;0.97])、0.43 (95% CI[0.32;0.55])和0.14 (95% CI [0.05;0.22]);实际生存率分别为0.83、0.36和0.29。结论:与风险评分相比,接受他汀类药物治疗的患者在5年和10年后的生存率更高。未使用他汀类药物的34例患者的生存率接近预期生存率。因此,应修改风险评分,纳入他汀类药物的使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
16.70%
发文量
208
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书